Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elaine R. Murray
Observed names:
E. Murray,
E.R. Murray,
Elaine Murray
Institution:
Genentech
Observed institution:
Genentech
ORCID:
0000-0001-9594-4845
Observed ORCID:
0000-0001-9594-4845
OpenAlex ID:
A5015747131
Pregnancy outcomes after maternal exposure to rituximab
2010
·
Eliza F. Chakravarty
, Elaine R. Murray
, et al.
·
Blood
·
620
PDF
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
2018
·
John C. Byrd
, Stephen Smith
, et al.
·
Oncotarget
·
89
PDF
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
2019
·
Andrea Varga
, Jean-Charles Soria
, et al.
·
Clinical Cancer Research
·
88
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
2018
·
A. Italiano
, J.R. Infante
, et al.
·
Annals of Oncology
·
83
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
2018
·
Ann E. Herman
, Leslie W. Chinn
, et al.
·
Clinical Pharmacology & Therapeutics
·
71
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
2016
·
Jeffrey R. Infante
, Antoine Hollebecque
, et al.
·
Clinical Cancer Research
·
71
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
2020
·
Colin Weekes
, Albert Lockhart
, et al.
·
The Oncologist
·
56
PDF
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF -mutated Urothelial Carcinoma
2021
·
Paul Rossman
, Tanja S. Zabka
, et al.
·
Molecular Cancer Therapeutics
·
40
PDF
A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
2016
·
A. Varga
, J.C. Soria
, et al.
·
European Journal of Cancer
·
17
Abstract CT107: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
2017
·
Colin D. Weekes
, Albert Lockhard
, et al.
·
Cancer Research
·
14
Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors
2015
·
Jeffrey R. Infante
, Antoine Hollebecque
, et al.
·
Cancer Research
·
7
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
2019
·
John C. Byrd
, Stephen Smith
, et al.
·
Oncotarget
·
2
PDF
Figure S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Data from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Supplementary Table S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Supplementary Table S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
PDF
Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S6 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S6 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Figure S4 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
2023
·
Paul Rossman
, Tanja S. Zabka
, et al.
Show more works
View as search
Works count:
39
Citation count:
1,158
H-index:
10
I10-index:
10
Year
Topic
Type